Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Andrew J Pierce

9PUBLICATIONS

85CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumours

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Mar 17, 2025

A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Johann S de Bono, Anja Williams, Ignacio Melero

|Jul 19, 2024

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.

Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio

|Apr 09, 2024

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.

Sophie Archer, Phillip M Brailey, Minjung Song

|Feb 24, 2024

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar

|Dec 31, 2021

The multi-specific V<sub>H</sub>-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.

Carolyn J Edwards, Angelica Sette, Carl Cox

|Oct 19, 2021

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.

Sophie E Willis, Claudia Winkler, Martine P Roudier

Pageof 2

Frequent Collaborators

2 joint publications

Philip Bland-Ward

2 joint publications

Johann S de Bono

2 joint publications

James Legg

2 joint publications

Phillip D Bartlett

2 joint publications

Neil R Birkett

1 joint publications

Peter Mortimer

1 joint publications

Kyoung-Mee Kim

1 joint publications

Timothy A Yap

1 joint publications

Matthew G Krebs

1 joint publications

Jeffrey R Whiteaker

Frequent Collaborators

2 joint publications

Philip Bland-Ward

2 joint publications

Johann S de Bono

2 joint publications

James Legg

2 joint publications

Phillip D Bartlett

Top Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on : Apr 24, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on : May 02, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on : Jan 29, 2019

See more related videos

Top Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on : Apr 24, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on : May 02, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on : Jan 29, 2019

See more related videos